4-异硫氰四羟基-1(2H)-吡啶甲酸苄酯 | 220394-91-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-异硫氰四羟基-1(2H)-吡啶甲酸苄酯
• 中文别名: 4-异氰酸基四氢-1(2H)-吡啶甲酸苄酯
• 英文名称: benzyl 4-isocyanatopiperidine-1-carboxylate
• 英文别名: benzyl 4-isocyanato-1-piperidinecarboxylate；benzyl 4-isocyanatotetrahydro-1(2H)-pyridinecarboxylate；4-isocyanato-piperidine-1-carboxylic acid benzyl ester；1-(benzyloxycarbonyl)-4-piperidinylisocyanate；(1-benzyloxycarbonylpiperidin-4-yl)isocyanate；benzyl 4-isocyanatopiperidin-1-carboxylate；4-isocyanato-Z-piperidine
• CAS: 220394-91-2
• 化学式: C₁₄H₁₆N₂O₃
• mdl: MFCD02681988
• 分子量: 260.293
• InChiKey: JBQXPARAPVCGFW-UHFFFAOYSA-N

物化性质

• 沸点：
  185 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  59
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 危险品运输编号：
  UN 2206
• 海关编码：
  2933399090

SDS

Name:	Benzyl 4-isocyanatotetrahydro-1(2H)-pyridinecarboxylate 97% Material Safety Data Sheet
Synonym:
CAS:	220394-91-2

Section 1 - Chemical Product MSDS Name:Benzyl 4-isocyanatotetrahydro-1(2H)-pyridinecarboxylate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
220394-91-2	Benzyl 4-isocyanatotetrahydro-1(2H)-py	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 220394-91-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Viscous liquid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 167 deg C @8mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H16N2O3
Molecular Weight: 260

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, alcohols, amines.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 220394-91-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Benzyl 4-isocyanatotetrahydro-1(2H)-pyridinecarboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: ISOCYANATE SOLUTION, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2206
Packing Group: III
IMO
Shipping Name: ISOCYANATE SOLUTION, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 2206
Packing Group: III
RID/ADR
Shipping Name: ISOCYANATE SOLUTION, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 2206
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 220394-91-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 220394-91-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 220394-91-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-异硫氰四羟基-1(2H)-吡啶甲酸苄酯 在 4-二甲氨基吡啶 作用下， 以 甲醇 为溶剂， 生成 benzyl 4-(methoxycarbonylamino)piperidine-1-carboxylate
  参考文献：
  名称：

  US6136827

  摘要：

  公开号：
• 作为产物：
  描述：

  4-氯羰酰四氢-吡啶羧酸苄酯 在 sodium azide 作用下， 以 丙酮 、 甲苯 为溶剂， 生成 4-异硫氰四羟基-1(2H)-吡啶甲酸苄酯
  参考文献：
  名称：

  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure–Activity relationships for 1-[N-(Methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes

  摘要：

  (2S)-2-(3-氯苯基)-1-[N-(甲基)-N-(苯磺酰基)氨基]-4-[螺环(2,3-二氢苯并噻吩-3,4'-哌啶-1'-基)]丁烷 S-氧化物 (lb) 已被鉴定为一种强效的 CCR5 拮抗剂，其 IC50 = 10 nM。在此，描述了非螺环哌啶的结构-活性关系研究，这些研究导致了发现 4-(N-(烷基)-N-(苯甲酰氧基)氨基)哌啶衍生物 (3-5) 作为强效的 CCR5 拮抗剂。(C) 2001 Elsevier Science Ltd. 保留所有权利。

  DOI：

  10.1016/s0960-894x(01)00492-9

文献信息

• An automated, polymer-assisted strategy for the preparation of urea and thiourea derivatives of 15-membered azalides as potential antimalarial chemotherapeutics
  作者：Antun Hutinec、Renata Rupčić、Dinko Žiher、Kirsten S. Smith、Wilbur Milhous、William Ellis、Colin Ohrt、Zrinka Ivezić Schönfeld

  DOI：10.1016/j.bmc.2011.01.030

  日期：2011.3

  series of 15-membered azalide urea and thiourea derivatives has been synthesized and evaluated for their in vitro antimalarial activity against chloroquine-sensitive (D6), chloroquine/pyremethamine resistant (W2) and multidrug resistant (TM91C235) strains of Plasmodium falciparum. We have developed an effective automated synthetic strategy for the rapid synthesis of urea/thiourea libraries of a macrolide

  合成了一系列15元氮杂内酰胺脲和硫脲衍生物，并评估了它们对恶性疟原虫的氯喹敏感性（D6），氯喹/乙胺嘧啶抗性（W2）和多药耐药性（TM91C235）菌株的体外抗疟活性。我们已经开发出一种有效的自动化合成策略，用于大环内酯支架的尿素/硫脲库的快速合成。使用溶液相策略合成化合物，总收率为50–80％。大多数合成的化合物具有抑制作用。前三种化合物对所有三种菌株的效力比阿奇霉素高30-65倍，阿奇霉素具有抗疟疾活性。
• Chemical compounds
  申请人：Faull Alan

  公开号：US20070167442A1

  公开（公告）日：2007-07-19

  Compounds of formula (I): compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).

  公式（I）的化合物：包括它们的组合物，制备它们的方法以及它们在医学疗法中的用途（例如在温血动物中调节CCR5受体活性）。
• 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
  申请人：Zask Arie

  公开号：US20090192176A1

  公开（公告）日：2009-07-30

  The invention relates to 1H-pyrazolo[3,4-d]pyrimidine, purine, 7H-purin-8(9H)-one, 3H-[1,2,3]triazolo[4,5-d]pyrimidine, and thieno[3,2-d]pyrimidine compounds, compositions comprising the compounds, and methods for making and using the compounds.

  这项发明涉及1H-吡唑并[3,4-d]嘧啶，嘌呤，7H-嘌呤-8(9H)-酮，3H-[1,2,3]三唑并[4,5-d]嘧啶和噻吩[3,2-d]嘧啶化合物，包含这些化合物的组合物，以及制备和使用这些化合物的方法。
• [EN] CYCLIC AMIDE DERIVATIVES, AND THEIR PRODUCTION AND USE AS ANTITHROMBOTIC AGENTS<br/>[FR] DÉRIVÉS D'AMIDES CYCLIQUES ET LEUR PRODUCTION ET UTILISATION COMME AGENTS ANTITHROMBOTIQUES
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005113504A1

  公开（公告）日：2005-12-01

  The present invention provides a cyclic amide derivative useful as a drug for treating thrombosis, which is represented by the formula (I): wherein R1 represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent chain hydrocarbon group, a represents 0, 1, or 2, X1 represents an optionally substituted lower alkylene or an optionally substituted lower alkenylene, Y1 represents -C(O)-, -S(O)- or -S(O)2-, A represents a piperazine ring which may be further substituted or a piperidine ring which may be further substituted, X2 represents a bond or an optionally substituted lower alkylene, Y2 represents -C(O)-, -S(O)-, -S(O)2- or -C(=NR7)-, X3 represents an optionally substituted C1-4 alkylene or an optionally substituted C2-4 alkenylene, Z3 represents -N(R4)-, -O- or a bond, Z1 represents -C(R2)(R2')-, -N(R2)-, etc., and Z2 represents -C(R3)(R3')-, -N(R3)-, etc., or a salt thereof.

  本发明提供了一种环酰胺衍生物，可用作治疗血栓症的药物，其化学式为（I）：其中R1代表一个可选择取代的环烃基或一个可选择取代的杂环基，W代表一个键或一个可选择取代的双价链烃基，a代表0、1或2，X1代表一个可选择取代的较低碳烷基或一个可选择取代的较低烯烃基，Y1代表-C（O）-、-S（O）-或-S（O）2-，A代表可能进一步取代的哌嗪环或可能进一步取代的哌啶环，X2代表一个键或一个可选择取代的较低碳烷基，Y2代表-C（O）-、-S（O）-、-S（O）2-或-C（=NR7）-，X3代表一个可选择取代的C1-4烷基或一个可选择取代的C2-4烯烃基，Z3代表-N（R4）-、-O-或一个键，Z1代表-C（R2）（R2'）-、-N（R2）-等，Z2代表-C（R3）（R3'）-、-N（R3）-等，或其盐。
• [EN] TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS<br/>[FR] ANTAGONISTES DE TRPM8 ET LEUR UTILISATION DANS LE CADRE THÉRAPEUTIQUE
  申请人：AMGEN INC

  公开号：WO2012177896A1

  公开（公告）日：2012-12-27

  Compounds of Formula (I) are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula (I) have the above structure, where the definitions of the variables are provided herein.

  式（I）的化合物可用作TRPM8的拮抗剂。这些化合物在治疗许多TRPM8介导的疾病和症状方面具有用处，并可用于制备用于治疗这些疾病和症状的药物和药物组合物。这些疾病的例子包括但不限于偏头痛和神经病性疼痛。式（I）的化合物具有上述结构，其中变量的定义在此提供。